in its press note to the exchanges on Thursday informed that the company re-launched its Buprenorphine and Naloxone Sublingual Film, 2 mg/0.5mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, a therapeutic equivalent generic version of Suboxone (buprenorphine and naloxone) sublingual film, in the US market after favorable ruling in patent litigation.
"The re-launch comes on the heels of a favorable decision issued by the US Court of Appeals for the Federal Circuit concluding that lndivior had not shown that it is likely to succeed on its claim that Dr. Reddy's product infringes US Patent No. 9,931,305," the company said in a press note the exchanges on Thursday.
The Federal Circuit's decision vacates the district court's preliminary injunction that had prohibited Dr. Reddy's from selling its generic version of Suboxone (buprenorphine and naloxone) sublingual film. The Federal Circuit's decision went into effective on February 20. "As a result of the Federal Circuit's ruling, Dr. Reddy's has resumed shipping of the product," the company added.
Dr Reddys Laboratories Ltd's share price ended at Rs2,530.10, up by Rs6.4 or 0.25%, from its previous close of Rs2,523.70 on the BSE.
The scrip opened at Rs2,530.10 and touched a high and low of Rs2,530.10 and Rs2,530.10, respectively. A total of, 3,157 (NSE+BSE) shares have traded on the counter. The current market cap of the company is Rs41,908.78cr.